Using continuous glucose monitoring in kidney transplant recipients with diabetes
Official title: Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients
Run by University of California, Davis · NCT04783441 · Data updated 2026-11-12
This study is testing if using a continuous glucose monitor can help kidney transplant recipients with Type 2 diabetes keep their blood sugar levels more stable.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | University of California, Davis Academic / other |
| Locations | 1 site (Sacramento, California) |
| Status | Recruiting |
| Started | June 29, 2021 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 29, 2026 |
| Trial ID | NCT04783441 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older who have received a kidney transplant within the past year and have Type 2 diabetes requiring insulin.
✕Probably not a fit
Patients with Type 1 diabetes or those with significant cognitive or visual impairments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of continuous glucose monitoring (CGM) on glycemic control in kidney transplant recipients who have Type 2 diabetes. The focus is on measuring time in range (TIR) for blood glucose levels between 70-180 mg/dL, which is crucial for managing diabetes post-transplant. Participants will use the Dexcom G6 device to track their glucose levels, allowing for better medication titration and management of glycemic variability. The study aims to address the challenges of maintaining glycemic control in the context of complex medication regimens and post-operative recovery.
Why it matters
Potential benefit: If successful, this approach could significantly improve glycemic control and overall health outcomes for kidney transplant recipients with diabetes.
How similar studies have gone: Previous studies have shown promising results with continuous glucose monitoring in diabetic populations, suggesting potential success for this approach in kidney transplant recipients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or above 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min 3. Person with Type 2 Diabetes and on insulin 4. Access to home wi-fi connection Exclusion Criteria: 1. Person with Type 1 Diabetes 2. Patients taking hydroxyurea 3. Patient unable to wear the Dexcom G6 device at all times for any reason 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM. 5. Presence of clinically significant visual or cognitive impairment 6. Illiterate 7. Prisoners 8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding 9. Presence of clinically unstable cardiovascular disease 10. Active malignancy treatment
Where it's running
-
UC Davis Health
Sacramento, California, United States Recruiting
Study contacts
- Study coordinator: Dahlia Zuidema, PharmD
- Email: dmzuidema@ucdavis.edu
- Phone: 916-734-4009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.